T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy
— Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need — Following CTA approval, Phase 1 ATLAS trial planned to begin in 2026 SAN FRANCISCO and BERLIN, Nov. 17, 2025 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a […]